Immediate Management of Suspected Acyclovir Neurotoxicity in ESRD
Immediately discontinue acyclovir and initiate daily hemodialysis—this is the definitive treatment that will result in rapid and complete neurological recovery within 24-48 hours 1.
Immediate Actions
1. Drug Withdrawal
- Stop acyclovir immediately upon suspicion of neurotoxicity 1
- Do not wait for confirmatory testing—the temporal relationship and clinical phenotype are sufficient for diagnosis
- The FDA label explicitly warns that approximately 1% of patients receiving IV acyclovir manifest encephalopathic changes (lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma), with particular caution needed in patients with renal impairment 1
2. Intensified Hemodialysis
- Initiate daily hemodialysis sessions (4-5 hours each) immediately 2, 3, 4
- Acyclovir is ideally suited for dialytic removal due to:
- Low protein binding (~15%)
- Small volume of distribution (0.6 L/kg)
- High water solubility 4
- A single 3-4 hour hemodialysis session removes approximately 45-51% of circulating acyclovir 3, 4
- Continue daily dialysis until complete neurological recovery (typically 2-3 consecutive sessions) 2
3. Supportive Care
- Airway protection and mechanical ventilation if GCS deteriorates to levels requiring intubation (as occurred in this case)
- Manage agitation and behavioral disturbances with minimal sedation to allow neurological monitoring
- Optimize cerebral perfusion and correct any electrolyte abnormalities 5
Diagnostic Work-Up
Essential Exclusions (Before Attributing to Acyclovir)
The critical diagnostic challenge is distinguishing acyclovir neurotoxicity from viral encephalitis—both occur in the setting of active herpes infection, but their management is opposite 5.
Key distinguishing features favoring acyclovir neurotoxicity:
- Temporal relationship: symptoms emerging 2-6 days after acyclovir initiation 2, 6, 7
- Unremarkable CSF: no pleocytosis, normal protein, negative infectious studies 5
- Normal neuroimaging: no meningeal enhancement, demyelination, or vasculopathy
- Prominent neuropsychiatric features (dysarthria, psychosis, delirium) rather than fever and focal deficits
- Progressive worsening despite stable metabolic parameters
Systematic exclusion pathway:
Neuroimaging (MRI brain with contrast, MRA, MRV)
- Rule out: PRES, vasculopathy, meningeal enhancement, demyelination, venous thrombosis
- In herpes zoster oticus: add CISS sequences for cranial nerve involvement and HRCT skull base for osteomyelitis
CSF analysis
- Cell count, protein, glucose
- HSV/VZV PCR and BioFire panel
- CSF CMMG level (9-carboxymethoxymethylguanine)—the acyclovir metabolite is detectable in CSF of symptomatic patients but undetectable in asymptomatic individuals; this provides diagnostic confirmation when available 1
EEG
- Rule out non-convulsive status epilepticus
- Acyclovir neurotoxicity typically shows generalized theta-delta slowing without epileptiform discharges or triphasic waves
Metabolic panel
- Exclude hepatic encephalopathy (ammonia level), uremia, electrolyte disturbances
- Note: neurological deterioration in acyclovir toxicity occurs despite stable metabolic parameters
Serum acyclovir and CMMG levels
- Serum CMMG is markedly elevated in symptomatic patients with renal impairment
- However, do not delay treatment while awaiting levels—clinical diagnosis is sufficient 2
Common Diagnostic Pitfall
Do not continue acyclovir while pursuing extensive autoimmune or paraneoplastic work-up. The medication history and temporal relationship should be reviewed before escalating to complex immunological investigations. Drug-induced neurotoxicity is reversible and should be excluded first.
Preventive Strategy
Dose Adjustment in ESRD
The case presentation notes acyclovir was given with "renal dose adjustment," yet toxicity still occurred—standard renal dosing recommendations are often insufficient for dialysis patients 8, 3.
Recommended dosing for hemodialysis patients 3:
- Loading dose: 400 mg orally (or 5 mg/kg IV)
- Maintenance: 200 mg orally twice daily (or 2.5 mg/kg IV)
- Post-dialysis supplementation: 400 mg after each dialysis session
- This maintains therapeutic levels (4-8 μM for VZV) while preventing accumulation
Medication Reconciliation
The 2020 AJKD guideline emphasizes that medication reconciliation is the foundation of medication safety in dialysis patients 8. Every acyclovir prescription in ESRD requires:
- Verification of actual creatinine clearance (not just "ESRD")
- Confirmation of dialysis schedule
- Explicit dose reduction beyond standard renal dosing tables
- Avoidance of nephrotoxic co-medications (particularly NSAIDs, which can precipitate toxicity) 7
Monitoring Protocol
For any dialysis patient receiving acyclovir:
- Daily neurological assessment for dysarthria, confusion, or behavioral changes
- Symptoms typically emerge within 2-6 days of treatment initiation
- Lower threshold for drug withdrawal if any neuropsychiatric symptoms develop
- Consider prophylactic daily dialysis during treatment course in high-risk patients
Expected Clinical Course After Intervention
Dramatic improvement occurs within 24-48 hours of drug withdrawal and intensified dialysis 2, 9:
- Neuropsychiatric symptoms (agitation, psychosis, hallucinations) improve after 1-2 dialysis sessions
- Complete resolution of encephalopathy typically by day 2-3
- Myoclonus and dysarthria resolve completely
- No residual neurological or cognitive deficits when promptly recognized and treated
If improvement does not occur within 48-72 hours of withdrawal and daily dialysis, reconsider the diagnosis—true viral encephalitis or another etiology becomes more likely.
Key Clinical Principle
The therapeutic response to acyclovir withdrawal and dialysis is both diagnostic and therapeutic 3. The rapid, complete neurological recovery following these interventions provides retrospective confirmation of the diagnosis, even without CMMG levels. This case exemplifies that meticulous medication review and recognition of temporal drug-symptom relationships can prevent unnecessary diagnostic escalation, prolonged ICU stays, and empirical immunotherapy in complex patients with unexplained encephalopathy.